Login to Your Account

Leo Pharma taps Morphosys to fuel dermatology ambitions

By Michael Fitzhugh
Staff Writer

Wednesday, November 2, 2016

Leo Pharma A/S is again raising its bet on the promise of biologics to address important skin diseases, dealing in Morphosys AG and its Ylanthia antibody platform for a multi-target deal.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription